Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast

Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprin...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical rheumatology Vol. 27; no. 8S; p. S561
Main Authors Charlton, Devon, Moghadam-Kia, Siamak, Smith, Kristin, Aggarwal, Rohit, English, 3rd, Joseph C, Oddis, Chester V
Format Journal Article
LanguageEnglish
Published United States 01.12.2021
Subjects
Dermatomyositis - complications
Dermatomyositis - diagnosis
Dermatomyositis - drug therapy
Female
Humans
Immunomodulating Agents
Immunosuppressive Agents
Pruritus - diagnosis
Pruritus - drug therapy
Pruritus - etiology
Scalp
Thalidomide - analogs & derivatives
Online AccessGet more information

Cover

More Information
Summary:Dermatomyositis (DM) is a subset of idiopathic inflammatory myopathy with characteristic cutaneous manifestations and muscle weakness. Conventional treatments for DM include glucocorticoids and other immunosuppressive or immunomodulatory agents including hydroxychloroquine, methotrexate, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, and intravenous immunoglobulin. Refractory patients require more aggressive or novel therapies. Apremilast has not been studied for the management of refractory cutaneous DM. We report a case of a patient with refractory DM with severe scalp pruritus treated with apremilast who demonstrated significant improvement in her skin disease and complete resolution of scalp pruritus.
ISSN:1536-7355
DOI:10.1097/RHU.0000000000000999